COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript

🇺🇸 Seeking Alpha (US) —
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript

AI Summary

COMPASS Pathways plc reported six-month data from their second Phase 3 trial, confirming a rapid and durable treatment profile for depression. The results support the efficacy of their therapy in managing depressive disorders.

Markets Health COMPASS Pathways Phase 3 trial depression treatment clinical trial biotech

Read original source →